Articles tagged with Tumor Growth
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers discovered that fine-tuning mitochondrial energy production reduces melanoma tumor growth and enhances immune response in mice. The study reveals that manipulating mitochondrial electron transport increases expression of immune genes and makes tumor cells more visible to killer T cells.
Researchers at City University of Hong Kong have developed a new class of near-infrared-activated photo-oxidants that can effectively kill cancer cells without requiring oxygen. The discovery offers a promising direction for developing anti-cancer drugs and could overcome existing limitations of photodynamic therapies.
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
A recent study published in PLOS Biology suggests that chemotherapy injury to surrounding non-cancer cells can awaken dormant breast cancer cells, promoting cancer growth and recurrence. The researchers found that the release of specific cell signaling molecules, G-CSF and IL-6, by injured stromal cells drives this process.
Researchers highlight microvascular contributions to white matter injury in Alzheimer's disease, sparking calls for exploration of connections between AD, WM injury and cerebral small vessel disease. The study emphasizes the critical need to define mechanisms and diagnostic features of mixed vascular and AD neuropathological change.
A new editorial paper explores the effectiveness of the third dose booster vaccine against SARS-CoV-2 in immunocompromised individuals. Researchers found that while the vaccine improves vaccine effectiveness across various measures, its benefits are not as significant for patients with cancer.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers discovered that a small subpopulation of AIB1-expressing cells in breast cancer enables invasion and metastasis. The study suggests that these subpopulations play a crucial role in tumor growth and spreading to distant sites.
Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The study found that activating a super-enhancer leads to an increase in protein production, enabling rapid cell growth.
A new study finds that targeting the ORAI1 calcium channel may provide a promising approach to treating oral cancer. The study reveals that activating this channel causes an influx of calcium into cancer cells, leading to increased pain sensitivity.
Researchers developed a targeted microRNA therapy that slowed cancer tumor growth in a 21-day study. The therapy, which combines a delivery system with modified microRNA-34a, suppressed the activity of genes driving cancer and resistance to other therapies.
Researchers found that antioxidants activate a mechanism forming new blood vessels in tumor cells, which can help them grow and spread. The study suggests that dietary supplements containing antioxidants may accelerate tumour growth and metastasis in cancer patients.
Researchers discovered that inhibiting IGF2BP1 can extinguish its cancer-causing effects, leading to the formation of neuroblastomas. The study provides a promising new potential therapeutic approach for treating this childhood cancer.
Researchers Elzbieta Izbicka and Robert T. Streeper discuss the evolution of cancer drug development, highlighting recent progress and emerging challenges due to environmental factors. They also examine how artificial intelligence may impact future drug development.
Researchers discuss the essential role of macrophages in metastatic growth of lung colonies in melanoma, highlighting their importance in clearing challenges to tissue integrity and promoting growth-related processes. The authors emphasize the need for targeted therapies against macrophages to combat untreatable metastasis.
Researchers have discovered that estrogen promotes tumor growth in ERα-negative cancers, such as triple-negative breast cancer. Anti-estrogenic therapies, when combined with immune checkpoint inhibitors, drastically suppress tumor progression in mice models.
Glutamine metabolism plays a crucial role in cancer cell growth and survival, with its inhibition shown to block cancer cell growth in vivo and in vitro. A recent editorial paper suggests that glutamine dysregulation may also impact the tumor microenvironment, potentially leading to increased oxidative stress and cancer cell death.
Researchers analyzed 10,000 proteins from 10 different cancers, identifying key drivers and interactions that fuel tumor growth. The study provides valuable insights into the molecular basis of cancer and may lead to new treatments targeting specific proteins or chemical alterations.
Researchers have found a promising new mechanism to target aggressive forms of prostate cancer, where the LSD1 protein is involved. By inhibiting LSD1, the tumor suppressor gene p53 can be reactivated, leading to suppression of tumor growth.
Researchers found that Epstein-Barr virus induces B cell growth transformation through the activation of the cancer-related gene IMPDH2, leading to uncontrolled proliferation. The study used primary B cells and found that inhibiting IMPDH2 can suppress post-transplant lymphoproliferative disorder (PTLD) development.
Researchers identified a mechanism regulating tumor growth in the skeleton, which decreases with age and can result from hormonal changes or chemotherapy. Mineralization of bone matrix reduces tumor cell growth and promotes genes associated with better patient prognosis.
Researchers highlight the need for effective treatment strategies for adenoid cystic carcinoma (ACC) of the head and neck, which is a highly malignant tumor with variable localizations. Proton therapy shows decisive advantages in long-term survival rates for ACC.
Researchers at UMass Amherst have discovered a potential new medical therapy for Lyme disease using lactate dehydrogenase inhibitors typically used to combat cancer. The study found that these inhibitors substantially impacted Borrelia burgdorferi growth, making them promising candidates against Lyme infections.
Workers cutting, grinding, and polishing artificial-stone slabs for countertops are developing silicosis due to high concentrations of silica and polymer resins. Researchers call for public health measures, including banning the product and improving worker safety.
A new editorial explores the potential of machine learning to enhance early cancer detection in primary care, leveraging extensive patient data and improving risk stratification accuracy. The authors emphasize the need for responsible implementation, collaboration, and validation across diverse populations.
Researchers found that epigallocatechin gallate (EGCG) reduces protein levels of fibronectin by 46-52% and disrupts pathways involved in fibroid tumor cell growth. EGCG supplements may provide an easily accessible and natural way to relieve symptoms and slow fibroid growth.
A study published in the Journal of the American Academy of Dermatology found that curettage and cryosurgery is an effective and safe treatment method for basal cell carcinoma. The procedure involves scraping the lesion with a curette followed by freezing, resulting in good outcomes with minimal side effects.
A UK-wide study found that non-functioning pituitary microadenomas (NFPA) are more likely to shrink or disappear than grow within three years of monitoring. The study suggests that clinical guidelines should be changed, and a single scan three years after initial detection would be a safe and cost-effective way to manage NFPAs.
A team of researchers identified TIM-1 as a key player in regulating anti-tumor immunity in melanoma. By targeting TIM-1, the immune system can activate killer T cells to inhibit tumor growth. The study's findings have significant implications for developing new cancer therapies.
A study by Martin-Luther-University Halle-Wittenberg found a link between high levels of IGF2BP2 and faster-growing bowel cancer tumours with chemotherapy resistance. The protein's role in cell growth and metabolism may lead to the development of new diagnostic procedures and therapeutic strategies.
A keto diet may help reduce body weight and slow tumor growth in cancer patients. However, research found that this diet can cause early-onset cachexia, a lethal wasting disease, in mice with pancreatic and colorectal cancer. Pairing keto with corticosteroids prevented cachexia in mice, allowing them to live longer.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Researchers achieve 3D printing within mini-organs growing in hydrogels, allowing for precise control over shape, activity, and tissue growth. This breakthrough enables the creation of realistic models of organs and disease, with potential applications in cancer research and treatment.
Researchers studied breast cancer cells that spread through the body and found a key mechanism driving their growth. The study reveals how cancer cells employ 'plasticity' to adopt properties promoting metastatic growth.
Cancer cells in brain tumors produce lipids at higher rates than surrounding healthy tissue, offering clues for treatment strategies. The study provides insights into the unique biochemical processes fueling cancer growth in the brain.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
A recent study led by UCLA researchers has identified a potential new strategy for treating glioblastoma by targeting a specific metabolic process in cancer cells. The study found that disrupting this process could make glioblastoma cells more vulnerable to cell death, offering hope for new treatment options.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers have identified three subtypes of ovarian high-grade serous carcinoma (HGSC) based on genomic changes, which may help tailor therapies. The study's findings could improve treatment outcomes for patients with this aggressive subtype.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
Brain cancer cells use mitochondria from healthy astrocytes to boost energy production and amplify cancer stem cells, making glioblastoma more deadly and difficult to treat. Researchers discovered that acquiring mitochondria is a common process in glioblastoma, with implications for developing new treatments.
Glioblastoma steals cognitive faculties as it spreads, but its insidious ability to infiltrate neighboring networks may be its undoing. Researchers found neural activity can restructure connections in surrounding tissue, causing decline. The drug gabapentin blocks this growth-causing activity in mice with glioblastoma.
Scientists have identified a specific gene mutation that triggers an inflammatory cascade, driving the development of treatment-resistant cancers. The study reveals a molecular circuitry by which mutations in the STK11 gene cause inflammation to spiral out of control.
Researchers at Baylor College of Medicine found that silencing gene p16 can drive colorectal cancer progression in animal models. A combined treatment strategy involving two drugs improved survival rates in tumor-bearing mice, offering new possibilities for targeted therapies.
A new study has provided insight into the mysterious evolution of DNA rings in tumors, revealing that nearly one-third of all tumors have these genetic structures. The researchers used a technology to trace the path of DNA ring development in neuroblastoma cells, finding that large rings contain cancer genes spurring cell growth.
Researchers have highlighted the importance of stromal vitamin A pathway in regulating IL-6 expression in colorectal cancer-associated fibroblasts. The study found that disrupting retinol-mediated IL-6 expression could be a potential approach to target CAFs during CRC treatment.
Researchers developed a method to predict DCIS progression to invasive breast cancer using mice with human DCIS cells. The study found molecular similarities between humans and mice, including the presence of HER2 protein increasing breast cancer risk.
A new study has shown that FAPI PET imaging is superior to standard FDG PET in evaluating multiple types of cancer. A newly designed FAP-targeted treatment also suppressed tumor growth in several common cancers, suggesting a powerful tool for the field of clinical nuclear medicine.
Researchers have identified ATAD3A as a molecular determinant that favors the development of head and neck cancer. The protein is involved in various cellular processes, including energy metabolism and apoptosis. Targeting ATAD3A could offer a novel approach to developing effective anti-cancer therapeutics.
The guideline provides guidance on definitive local therapy options for non-small cell lung cancer with limited extracranial metastases. It emphasizes the need for a patient-centered, multidisciplinary approach to treatment decisions.
A novel cell signaling pathway has been identified that could be targeted to treat aggressive pancreatic cancers. The High Mobility Group A1 (HMGA1) protein functions as a 'molecular switch' that activates genes required for tumor growth and invasion. Silencing HMGA1 or disrupting FGF19 signals in mouse models resulted in decreased tum...
A team of researchers has discovered that a naturally produced chemical in the body helps glioblastoma cells go unrecognized by the immune system. The findings could lead to the development of new and more effective treatments for this aggressive brain cancer.
Acute myeloid leukemia is a cancer that affects blood cells and can lead to infection, anemia, and easy bleeding. The Georgia Cancer Center has received a $2.3 million grant to study how cancer cells resist treatment and propose new options to improve patient survival.
Scientists discovered that deleting a protein called sphingosine kinase 2 (SphK2) reprograms the tumor microenvironment, decreasing S1P levels and increasing p53 tumor suppressor gene accumulation. This creates an inhospitable environment for aggressive breast tumors.
Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.
Researchers found that neutrophils can be pro- or anti-tumour depending on their surface markers, and those fighting tumours share cytotoxic power with neutrophils in bacterial infections. Blocking these anti-tumour neutrophils eliminates treatment benefits.
Researchers at Georgia Institute of Technology developed a synthetic tumor model to understand the impact of microenvironment on targeted therapies for Activated B Cell-like Diffuse Large B cell lymphoma. The model showed promise in demonstrating how combining therapeutics can overcome tumor resistance to inhibitors.
Researchers developed a 3D cell culture system to test fibroblast inhibitors with anti-cancer drugs. Combining nintedanib with cisplatin increased the latter's efficacy in suppressing cancer growth and invasion. The study provides a promising tool for preclinical drug testing.